Stratipath

Stratipath is a Swedish healthcare company that focuses on precision medicine, particularly in cancer treatment. Founded in 2019 as a spin-out from Karolinska Institutet in Stockholm, the company combines the expertise of clinicians, researchers, and AI specialists to create advanced diagnostic tools aimed at improving patient outcomes. The core product, Stratipath Breast, is an AI-driven prognostic risk profiling tool for invasive breast cancer. It analyzes routine histopathology images to classify tumors into high- and low-risk categories, providing quick insights for oncologists and pathologists. This solution integrates easily into existing pathology workflows and is compliant for clinical use in Europe and the UK. Stratipath's technology leverages machine learning and deep learning methods to enhance precision diagnostics and reduce healthcare costs. Stratipath primarily serves oncology clinics, pathology laboratories, and hospitals, offering its solutions as Software as a Service (SaaS) integrated with digital pathology platforms. The company has formed strategic partnerships, such as with Diagnexia, to broaden the availability of its AI-based cancer diagnostics across the UK and Europe.

• Employees 16
• Founded 2019